PT Inquest is an online journal club. Hosted by Jason Tuori, Megan Graham, and Chris Juneau, the show looks at an article every week and discusses how it applies to current physical therapy practice.
…
continue reading
Content provided by ReachMD. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by ReachMD or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!
Go offline with the Player FM app!
The Gene Messenger: Advancing Neurological Gene Therapy
MP3•Episode home
Manage episode 424756766 series 1103955
Content provided by ReachMD. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by ReachMD or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Guest: Michael Kaplitt, MD, PhD
For the first time, Dr. Michael Kaplitt was able to perform a trial for a neurological gene therapy that was administered in a human patient to address damaged brain cells caused by Parkinson’s disease. This procedure used an adeno-associated virus to deliver a gene into the brain of a patient with Parkinson’s. The results were groundbreaking and paved new avenues for research in neurological gene therapy, such as preventative intervention. Join health and science journalist Catherine Price as she speaks with Dr. Michael Kaplitt, Executive Vice Chair of the Department of Neurological Surgery at NewYork-Presbyterian/Weill Cornell Medicine, as he discusses the story of his breakthrough and how he’s continuing to evolve the field of neurosurgery.
…
continue reading
For the first time, Dr. Michael Kaplitt was able to perform a trial for a neurological gene therapy that was administered in a human patient to address damaged brain cells caused by Parkinson’s disease. This procedure used an adeno-associated virus to deliver a gene into the brain of a patient with Parkinson’s. The results were groundbreaking and paved new avenues for research in neurological gene therapy, such as preventative intervention. Join health and science journalist Catherine Price as she speaks with Dr. Michael Kaplitt, Executive Vice Chair of the Department of Neurological Surgery at NewYork-Presbyterian/Weill Cornell Medicine, as he discusses the story of his breakthrough and how he’s continuing to evolve the field of neurosurgery.
© 2024 NewYork-Presbyterian
47 episodes
MP3•Episode home
Manage episode 424756766 series 1103955
Content provided by ReachMD. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by ReachMD or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Guest: Michael Kaplitt, MD, PhD
For the first time, Dr. Michael Kaplitt was able to perform a trial for a neurological gene therapy that was administered in a human patient to address damaged brain cells caused by Parkinson’s disease. This procedure used an adeno-associated virus to deliver a gene into the brain of a patient with Parkinson’s. The results were groundbreaking and paved new avenues for research in neurological gene therapy, such as preventative intervention. Join health and science journalist Catherine Price as she speaks with Dr. Michael Kaplitt, Executive Vice Chair of the Department of Neurological Surgery at NewYork-Presbyterian/Weill Cornell Medicine, as he discusses the story of his breakthrough and how he’s continuing to evolve the field of neurosurgery.
…
continue reading
For the first time, Dr. Michael Kaplitt was able to perform a trial for a neurological gene therapy that was administered in a human patient to address damaged brain cells caused by Parkinson’s disease. This procedure used an adeno-associated virus to deliver a gene into the brain of a patient with Parkinson’s. The results were groundbreaking and paved new avenues for research in neurological gene therapy, such as preventative intervention. Join health and science journalist Catherine Price as she speaks with Dr. Michael Kaplitt, Executive Vice Chair of the Department of Neurological Surgery at NewYork-Presbyterian/Weill Cornell Medicine, as he discusses the story of his breakthrough and how he’s continuing to evolve the field of neurosurgery.
© 2024 NewYork-Presbyterian
47 episodes
All episodes
×Welcome to Player FM!
Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.